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Individuals with both type 1 and type 2 diabetes show vascular complications that may remain 
undetected for many years until the disease is at an advanced stage. Clinical trials to date have been 
unsuccessful in identifying a therapeutic approach that addresses the underlying problem in diabetes, 
poor glycaemic control while also reducing incidence of microvascular disease (1). Oxidative stress; an 
imbalance of oxidants and antioxidants in the favour of oxidants has been considered to play a central 
part in protein glycation and complications in diabetes (2-4). Neutralisation of oxidants by increased 
antioxidant availability has been considered as one possible way to mitigate oxidative stress. Indeed, 
several human intervention studies have been undertaken to determine whether dietary antioxidants 
can exert any beneficial effects for T2DM patients (5, 6).  
Chronically elevated levels of glucose increase the frequency of non-enzymatic glucose-adduction with 
proteins, lipids and DNA to form advanced glycated end products (AGEs). One of the major plasma 
proteins that can undergo secondary modification by glucose or oxidised lipids in diabetes is the 
cholesterol carrying low density lipoprotein (LDL). In Type 2 diabetic patients, LDL are more glycated 
and more susceptible to oxidation (7) increasing their clearance by macrophages in a non-regulated 
manner and increasing foam cell formation.  
Complications such as microalbuminuria, are associated with renal protein oxidation, which is in turn 
preceded by LDL fatty acid oxidation. The initiator is H2O2 produced from an auto-oxidation of 
homocysteine and increased metabolism of arachidonic acid towards its pro-inflammatory eicosanoids. 
The backdrop of increased oxidative stress state promotes a state of diffused vasculopathy (8). 
In both type 1 and type 2 diabetes patients, there is an increased risk of cognitive impairment in later 
life. In the glucose control intervention study, cognitive function was an independent predictor of  
glycaemic control, and the risk of cognitive decline or dementia is not decreased by improving blood 
glucose levels (9). The presence of AGEs and carbonylation of LDL, which is indicative of oxidative 
stress and glycation are shared common risk factors for both diabetes and cognitive impairment (10, 
11).  
Free radicals, AGEs and biomarkers 
The generation of free radicals physiologically is a common phenomenon (12). Where there is an 
imbalance between radical production and scavenging, their detrimental effects on macromolecules are 
observed (11, 13). Owing to their high rates of reaction with biological macromolecules they cannot be 
easily monitored directly unless trapped for example by a biological molecule or through reacting with 
biomolecules to form stable end-products of radical attack.  
Accumulating evidence suggests that AGEs are involved in a vicious cycle of generating free radicals 
(14, 15). AGEs increase the expression and activity of NADPH (nicotinamide adenine dinucleotide 
phosphate) oxidase in human endothelial cells, an important source of vascular oxidative stress in type 
2 diabetes (16). Increased NADPH oxidase activity results in formation of free radicals, depletion of 
cellular antioxidants such as glutathione, glutathione peroxidase, superoxide dismutase and catalase. 
Free radical mediated lipid peroxidation of polyunsaturated fatty acids gives rise to formation of several 
reactive α-, β-unsaturated aldehydes such as 4-hydroxy-trans-2-nonenal (HNE), 4-oxotrans-2-nonenal 
(4-ONE), acrolein and 4-oxo-trans-2-hexanal, all of which are aldehydes like glucose, have the potential 
to be considered as biomarkers of glycaemic status but can also form advanced lipid peroxidation end 
products (ALE). The detection of 4-HNE and malondialdehyde (MDA) adducts, and oxLDLs within the 
atherosclerotic plaque is an hallmark in atherosclerosis (17). Similarly, the radical oxidised lipid, MDA 
has been shown to generate ALE and together with AGEs these cause secondary damage to proteins 
(15). 8-iso-PGF2α, is widely used as a biomarker of lipid oxidation. It is measured in plasma or urine by 
mass spectrometry techniques or enzyme-linked immunosorbent assay (ELISA). However, 
discrepancies between the specificity of these methods means care must be taken when interpreting 
findings between different studies (18).  Nevertheless, it is widely adopted as a marker for measuring in 
vivo lipid oxidation and a recent meta-analysis considered F2-isoprostanes, considered the evidence for 
its association with coronary artery disease, stroke and peripheral artery disease. These authors 
considered the differences in sample handling/storage and assays as key contributors to the variation 
between studies. Nevertheless, high levels of F2-isoprostanes in urine or blood did appear to be a non-
specific indicator of CVD and should be explored in prospective studies (19). 
Given the rapidly increasing incidence of type 1 diabetes and obesity-associated type 2 diabetes in 
mid-life which contributes to increased risk for dementia, recently termed type 3 diabetes, there is an 
urgent need to understand how systemic changes in metabolism may predispose to dementia in order 
to develop early risk biomarkers which can be applied for monitoring health outcomes. With sufficient 
care taken in sample collection coupled with analytical precision, F2-isoprostanes may prove to be very 
useful and offer improved bio-monitoring opportunities to support the implementation of strategies to 
minimise vascular complications. 
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